Johnson & Johnson Receives European Commission Approval for Rybrevant Plus Lazertinib in NSCLC

Johnson & Johnson today announced that the European Commission has approved Rybrevant (amivantamab-vmjw) in combination with lazertinib for the first-line treatment of adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in the European Union. The approval was based on results from the Phase 3 MARIPOSA trial, which demonstrated superior progression-free survival compared to osimertinib. This approval makes Rybrevant plus lazertinib available as a first-line treatment option for EGFR-mutated NSCLC patients across all EU member states.